\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital Europe HPC AI Continent Cybersecurity Advanced Digital Skills Deployment: Best use of technologies Semiconductors European Digital Innovation HubsThe European Commission is still collecting input on the Digital Europe programme by means of two consultations. The results of these consultations will feed into the mid-term evaluation of Digital Europe.
The Open Stakeholder Consultation seeks to gain insights into the needs of stakeholders in the digital transformation, the perceived benefits of Digital Europe, and how the programme could be improved. As such, it aims to gather diverse perspectives from SMEs to NGOs, academia, social partners, public authorities, and other public and private organisations and citizens from EU Member States and countries associated to the programme. The consultation will also be an opportunity to assess the first results achieved.
Deadline to respond to this consultation is 20 September.
If your organisation is a beneficiary in one or several Digital Europe projects, you most probably have received an invitation by email to respond to the Beneficiary Survey.
Please note that - while held in the same context to prepare the mid-term evaluation of Digital Europe - this is a different survey than the Open Stakeholder Consulation, and the deadline to respond to this survey is 13 September.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
